Pierre-Antoine Bonnet

List of Publications by Year
in descending order

50 papers	1,260 citations	361296 20 h-index	360920 35 g-index
52 all docs	52 docs citations	52 times ranked	1504 citing authors

#	Article	IF	Citations
1	EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML. International Journal of Molecular Sciences, 2022, 23, 3421.	1.8	7
2	Imidazo[1,2-a]quinoxalines for melanoma treatment with original mechanism of action. European Journal of Medicinal Chemistry, 2021, 212, 113031.	2.6	11
3	Fused Azolo-Quinoxalines: Candidates for Medicinal Chemistry. A Review of their Biological Applications. Current Medicinal Chemistry, 2021, 28, 712-749.	1.2	1
4	Imiquimod Targets Toxoplasmosis Through Modulating Host Toll-Like Receptor-MyD88 Signaling. Frontiers in Immunology, 2021, 12, 629917.	2.2	12
5	An in-line enzymatic microreactor for the middle-up analysis of monoclonal antibodies by capillary electrophoresis. Analyst, The, 2020, 145, 1759-1767.	1.7	16
6	Substantial Cellular Penetration of Fluorescent Imidazoquinoxalines. Journal of Fluorescence, 2020, 30, 1499-1512.	1.3	1
7	Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. European Journal of Medicinal Chemistry, 2020, 193, 112238.	2.6	77
8	Novel and Selective TLR7 Antagonists among the Imidazo[1,2-a]pyrazines, Imidazo[1,5-a]quinoxalines, and Pyrazolo[1,5-a]quinoxalines Series. Journal of Medicinal Chemistry, 2019, 62, 7015-7031.	2.9	31
9	Methylation of imidazopyrazine, imidazoquinoxaline, and pyrazoloquinoxaline through Suzukiâ€“Miyaura cross coupling. Chemistry of Heterocyclic Compounds, 2018, 54, 183-187.	0.6	3
10	Raman chemical imaging for spectroscopic screening and direct quantification of falsified drugs. Journal of Pharmaceutical and Biomedical Analysis, 2018, 148, 316-323.	1.4	35
11	Liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitative estimation of new imiqualine leads with potent anticancer activities in rat and mouse plasma. Application to a pharmacokinetic study in mice. Journal of Pharmaceutical and Biomedical Analysis, 2018, 148, 369-379.	1.4	2
12	Imidazo[1,2-a]quinoxalines Derivatives Grafted with Amino Acids: Synthesis and Evaluation on A375 Melanoma Cells. Molecules, 2018, 23, 2987.	1.7	12
13	EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica. PLoS Neglected Tropical Diseases, 2018, 12, e0006854.	1.3	24
14	Fluorescence Study of Imidazoquinoxalines. Journal of Fluorescence, 2017, 27, 1607-1611.	1.3	5
15	Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline andÂPyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors. European Journal of Medicinal Chemistry, 2017, 138, 909-919.	2.6	22
16	Lipid nanocapsules formulation and cellular activities evaluation of a promising anticancer agent: EAPB0503. International Journal of Pharmaceutical Investigation, 2017, 7, 155.	0.2	5
17	New imidazoquinoxaline derivatives: Synthesis, biological evaluation on melanoma, effect on tubulin polymerization and structureâ€“activity relationships. Bioorganic and Medicinal Chemistry, 2016, 24, 2433-2440.	1.4	32
18	New IKK inhibitors: Synthesis of new imidazo[1,2-a]quinoxaline derivatives using microwave assistance and biological evaluation as IKK inhibitors. European Journal of Medicinal Chemistry, 2016, 115, 268-274.	2.6	16

#	Article	IF	Citations
19	EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells. Anti-Cancer Drugs, 2014, 25, 624-632.	0.7	15
20	Identification and quantification of 14 phthalates and 5 non-phthalate plasticizers in PVC medical devices by GCâ€“MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 949-950, 99-108.	1.2	125
21	Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatographyâ€“tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 429-440.	1.4	10
22	Analytical method for the identification and assay of 12 phthalates in cosmetic products: Application of the ISO 12787 international standard â€œCosmeticsâ€“Analytical methodsâ€“Validation criteria for analytical results using chromatographic techniquesâ€• Journal of Chromatography A, 2012, 1253, 144-153.	1.8	47
23	Characterization of a New Anticancer Agent, EAPB0203, and Its Main Metabolites: Nuclear Magnetic Resonance and Liquid Chromatographyâ€“Mass Spectrometry Studies. Analytical Chemistry, 2012, 84, 9865-9872.	3.2	12
24	Nutritional Supplements. , 2012, , 539-573.		0
25	Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma. European Journal of Pharmaceutical Sciences, 2010, 39, 23-29.	1.9	24
26	Metabolism and Pharmacokinetics of EAPB0203 and EAPB0503, Two Imidazoquinoxaline Compounds Previously Shown to Have Antitumoral Activity on Melanoma and T-Lymphomas. Drug Metabolism and Disposition, 2010, 38, 1836-1847.	1.7	14
27	HMOX1 and NQO1 Genes are Upregulated in Response to Contact Sensitizers in Dendritic Cells and THP-1 Cell Line: Role of the Keap1/Nrf2 Pathway. Toxicological Sciences, 2009, 107, 451-460.	1.4	126
28	Quantitation of imidazo[1,2â€‹a]quinoxaline derivatives in human and rat plasma using LC/ESIâ€MS. Journal of Separation Science, 2009, 32, 1363-1373.	1.3	11
29	New imidazo[1,2-a]quinoxaline derivatives: Synthesis and in vitro activity against human melanoma. European Journal of Medicinal Chemistry, 2009, 44, 3406-3411.	2.6	45
30	In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 6601-6610.	1.4	104
31	EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-Iâ€“associated adult T-cell leukemia/lymphoma. Blood, 2008, 111, 3770-3777.	0.6	36
32	Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 850, 376-383.	1.2	54
33	The cytokine-dependent MUTZ-3 cell line as an in vitro model for the screening of contact sensitizers. Toxicology and Applied Pharmacology, 2006, 212, 14-23.	1.3	90
34	Qualitative and quantitative evaluation of a local lymph node assay based on ex vivo interleukin-2 production. Toxicology, 2005, 206, 285-298.	2.0	18
35	Design and synthesis of novel imidazo[1,2- a]quinoxalines as PDE4 inhibitors. Bioorganic and Medicinal Chemistry, 2004, 12, 1129-1139.	1.4	30
36	Imidazo[1,2-a]quinoxalines: synthesis and cyclic nucleotide phosphodiesterase inhibitory activity. European Journal of Medicinal Chemistry, 2001, 36, 255-264.	2.6	26

#	Article	IF	Citations
37	Tungsten determination in rat and dog plasma samples by inductively coupled plasma emission spectrometry. Analytica Chimica Acta, 2000, 405, 221-226.	2.6	20
38	New imidazo[1,2-a]pyrazine derivatives with bronchodilatory and cyclic nucleotide phosphodiesterase inhibitory activities. Bioorganic and Medicinal Chemistry, 1999, 7, 1059-1065.	1.4	24
39	VASORELAXANT EFFECTS OF SCA40 (A PHOSPHODIESTERASE III INHIBITOR) IN PULMONARY VASCULAR PREPARATIONS IN RATS. Clinical and Experimental Pharmacology and Physiology, 1998, 25, 355-360.	0.9	7
40	Antiproliferative effects of imidazo[1,2-Î²]pyrazine derivatives on the dami cell line. Biochemical Pharmacology, 1997, 54, 365-371.	2.0	3
41	Effects of SCA40 on bovine trachealis muscle and on cyclic nucleotide phosphodiesterases. European Journal of Pharmacology, 1997, 334, 75-85.	1.7	4
42	Dissociation between phosphodiesterase inhibition and antiproliferative effects of phosphodiesterase inhibitors on the dami cell line. Biochemical Pharmacology, 1997, 53, 1141-1147.	2.0	11
43	Interaction and translocation of cysteamine (mercaptoethylamine) with model membranes: a 15N-NMR and 1H-NMR study. European Journal of Pharmaceutics and Biopharmaceutics, 1997, 43, 73-81.	2.0	3
44	Apoptotic effects of imidazo[1,2-a]pyrazine derivatives in the human Dami cell line. European Journal of Pharmacology, 1997, 320, 215-221.	1.7	3
45	Modulation of the Megakaryoblastic Dami Cell Line Differentiation by Phosphodiesterase Inhibitors and Imidazo[1,2â€‹a]pyrazine Derivatives. Basic and Clinical Pharmacology and Toxicology, 1997, 80, 286-289.	0.0	1
46	Nitration in the imidazo[1,2â€‹a]pyrazine series. Experimental and computational results. Journal of Heterocyclic Chemistry, 1997, 34, 701-707.	1.4	8
47	Isolation and structure elucidation of a highly haemolytic saponin from the Merck saponin extract using high-field gradient-enhanced NMR techniques. Carbohydrate Research, 1997, 302, 67-78.	1.1	29
48	Relaxivity enhancement of low molecular weight nitroxide stable free radicals: Importance of structure and medium. Magnetic Resonance in Medicine, 1994, 32, 11-15.	1.9	31
49	Carboxylic acid or primary amine titration at the lipid-water interface: on the role of electric charges and phospholipid acyl chain composition. A spin labeling experiment. Chemistry and Physics of Lipids, 1990, 55, 133-143.	1.5	14
50	Stearic acid pH-dependent reactivity in dipalmitoyl phosphatidylcholine model membranes in LÎ²â€² gel phase. An electron spin resonance and differential scanning calorimetry experiment. Journal of the Chemical Society Faraday Transactions I, 1989, 85, 3587.	1.0	3